rs554570575
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PM2PM4
The NM_000428.3(LTBP2):c.804_821delGCCCGCACCACAGTCGCC(p.Pro269_Pro274del) variant causes a disruptive inframe deletion change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000206 in 1,613,680 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Genomes: 𝑓 0.00022 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00020 ( 0 hom. )
Consequence
LTBP2
NM_000428.3 disruptive_inframe_deletion
NM_000428.3 disruptive_inframe_deletion
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 1.65
Genes affected
LTBP2 (HGNC:6715): (latent transforming growth factor beta binding protein 2) The protein encoded by this gene belongs to the family of latent transforming growth factor (TGF)-beta binding proteins (LTBP), which are extracellular matrix proteins with multi-domain structure. This protein is the largest member of the LTBP family possessing unique regions and with most similarity to the fibrillins. It has thus been suggested that it may have multiple functions: as a member of the TGF-beta latent complex, as a structural component of microfibrils, and a role in cell adhesion. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 4 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PM4
Nonframeshift variant in NON repetitive region in NM_000428.3.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LTBP2 | ENST00000261978.9 | c.804_821delGCCCGCACCACAGTCGCC | p.Pro269_Pro274del | disruptive_inframe_deletion | 3/36 | 1 | NM_000428.3 | ENSP00000261978.4 | ||
LTBP2 | ENST00000556690.5 | c.804_821delGCCCGCACCACAGTCGCC | p.Pro269_Pro274del | disruptive_inframe_deletion | 3/35 | 5 | ENSP00000451477.1 | |||
LTBP2 | ENST00000553939.5 | n.804_821delGCCCGCACCACAGTCGCC | non_coding_transcript_exon_variant | 3/36 | 5 | ENSP00000452110.1 | ||||
LTBP2 | ENST00000557425.1 | n.123+26166_123+26183delGCCCGCACCACAGTCGCC | intron_variant | 2 |
Frequencies
GnomAD3 genomes AF: 0.000224 AC: 34AN: 152076Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
34
AN:
152076
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000181 AC: 45AN: 249146Hom.: 0 AF XY: 0.000185 AC XY: 25AN XY: 134872
GnomAD3 exomes
AF:
AC:
45
AN:
249146
Hom.:
AF XY:
AC XY:
25
AN XY:
134872
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000205 AC: 299AN: 1461604Hom.: 0 AF XY: 0.000206 AC XY: 150AN XY: 727114
GnomAD4 exome
AF:
AC:
299
AN:
1461604
Hom.:
AF XY:
AC XY:
150
AN XY:
727114
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000224 AC: 34AN: 152076Hom.: 0 Cov.: 32 AF XY: 0.000269 AC XY: 20AN XY: 74294
GnomAD4 genome
AF:
AC:
34
AN:
152076
Hom.:
Cov.:
32
AF XY:
AC XY:
20
AN XY:
74294
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Weill-Marchesani syndrome 3 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | 3billion | May 22, 2022 | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.016%). Inframe deletion located in a nonrepeat region: predicted to change the length of the protein and disrupt normal protein function. Therefore, this variant is classified as uncertain significanceaccording to the recommendation of ACMG/AMP guideline. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 30, 2022 | This variant, c.804_821del, results in the deletion of 6 amino acid(s) of the LTBP2 protein (p.Pro271_Ala276del), but otherwise preserves the integrity of the reading frame. This variant is present in population databases (rs757670961, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with LTBP2-related conditions. ClinVar contains an entry for this variant (Variation ID: 1365526). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
LTBP2-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Apr 09, 2024 | The LTBP2 c.804_821del18 variant is predicted to result in an in-frame deletion (p.Pro271_Ala276del). To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.034% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at